NASDAQ:IMVT - Immunovant Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.75
  • Forecasted Upside: 243.18 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.09 (-0.81%)

This chart shows the closing price for IMVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunovant Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMVT

Analyst Price Target is $37.75
▲ +243.18% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $37.75, with a high forecast of $63.00 and a low forecast of $9.00. The average price target represents a 243.18% upside from the last price of $11.00.

This chart shows the closing price for IMVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Immunovant.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/2/2021Credit Suisse GroupBoost Price TargetNeutral$12.00 ➝ $26.00Low
6/2/2021SVB LeerinkLower Price TargetOutperform$38.00 ➝ $17.00Medium
6/2/2021Robert W. BairdLower Price TargetOutperform$32.00 ➝ $20.00High
6/2/2021HC WainwrightLower Price TargetBuy$23.00 ➝ $19.00High
6/1/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/1/2021GuggenheimDowngradeBuy ➝ NeutralHigh
6/1/2021Stifel NicolausDowngradeBuy ➝ Hold$28.00 ➝ $9.00High
5/10/2021HC WainwrightLower Price TargetBuy$33.00 ➝ $23.00High
2/16/2021Stifel NicolausReiterated RatingBuy$28.00Low
2/3/2021Raymond JamesLower Price TargetOutperform$58.00 ➝ $35.00Medium
2/3/2021SVB LeerinkLower Price TargetOutperform$52.00 ➝ $38.00High
2/3/2021HC WainwrightLower Price TargetBuy$54.00 ➝ $33.00High
2/2/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
2/2/2021Stifel NicolausLower Price TargetBuy$54.00 ➝ $33.00Low
1/13/2021HC WainwrightReiterated RatingBuy$54.00High
11/13/2020TruistBoost Price Target$52.00 ➝ $62.00Medium
11/13/2020Robert W. BairdBoost Price TargetOutperform$47.00 ➝ $64.00Medium
11/13/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $54.00High
11/13/2020SVB LeerinkBoost Price TargetOutperform$39.00 ➝ $52.00High
11/12/2020Chardan CapitalBoost Price Target$45.00 ➝ $60.00High
10/28/2020UBS GroupInitiated CoverageBuy$61.00Medium
10/12/2020GuggenheimInitiated CoverageBuy$63.00Medium
10/7/2020Stifel NicolausInitiated CoverageBuy$46.00Medium
10/6/2020Lifesci CapitalReiterated RatingOutperformHigh
10/2/2020CSFBInitiated CoverageOutperform$49.00High
10/2/2020Credit Suisse GroupInitiated CoverageOutperform$49.00High
8/26/2020TruistBoost Price Target$36.00 ➝ $52.00Low
8/26/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00High
8/25/2020Robert W. BairdBoost Price TargetOutperform$31.00 ➝ $47.00Medium
8/25/2020Chardan CapitalBoost Price TargetPositive ➝ Buy$35.00 ➝ $45.00Medium
8/24/2020Raymond JamesInitiated CoverageOutperform$35.00High
8/20/2020SVB LeerinkBoost Price TargetOutperform ➝ Outperform$26.00 ➝ $34.00Medium
8/13/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $35.00High
8/5/2020Ci CapitalReiterated RatingBuy$32.00Medium
7/29/2020HC WainwrightInitiated CoverageBuy$34.00Medium
6/18/2020SunTrust BanksUpgradeBuyHigh
6/17/2020SunTrust BanksBoost Price Target$24.00 ➝ $36.00Low
5/29/2020NomuraBoost Price TargetBuy$27.00 ➝ $37.00High
5/29/2020Nomura InstinetBoost Price TargetBuy$27.00 ➝ $37.00High
3/4/2020Nomura SecuritiesReiterated RatingBuy$27.00Medium
2/24/2020SVB LeerinkInitiated CoverageOutperform$24.00High
2/17/2020Chardan CapitalReiterated RatingBuyMedium
2/4/2020Nomura SecuritiesInitiated CoverageBuy$27.00High
1/10/2020SunTrust BanksInitiated CoverageBuy$24.00High
1/9/2020Chardan CapitalInitiated CoverageBuy$30.00High
1/7/2020Robert W. BairdInitiated CoverageOutperform$21.00Medium
(Data available from 6/24/2016 forward)
Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $11.00
Low: $10.94
High: $11.43

50 Day Range

MA: $13.94
Low: $9.40
High: $16.76

52 Week Range

Now: $11.00
Low: $9.22
High: $53.75


408,166 shs

Average Volume

1,403,799 shs

Market Capitalization

$1.08 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Immunovant?

The following equities research analysts have issued research reports on Immunovant in the last twelve months: Chardan Capital, Ci Capital, Credit Suisse Group AG, CSFB, Guggenheim, HC Wainwright, Lifesci Capital, Raymond James, Robert W. Baird, Stifel Nicolaus, SVB Leerink LLC, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for IMVT.

What is the current price target for Immunovant?

12 Wall Street analysts have set twelve-month price targets for Immunovant in the last year. Their average twelve-month price target is $37.75, suggesting a possible upside of 243.2%. Guggenheim has the highest price target set, predicting IMVT will reach $63.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $9.00 for Immunovant in the next year.
View the latest price targets for IMVT.

What is the current consensus analyst rating for Immunovant?

Immunovant currently has 4 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMVT will outperform the market and that investors should add to their positions of Immunovant.
View the latest ratings for IMVT.

What other companies compete with Immunovant?

How do I contact Immunovant's investor relations team?

Immunovant's physical mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company's listed phone number is 917-580-3099. The official website for Immunovant is